September 27, 2016 7:28am

… JUNO and BLCM experience the tailwinds

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is “our” universe going today?  Astute investors subscribe, you should too! 

 

I say what others won't, so you can do what others can't!

 

 

 

How does the old saying go? It's easier to ask for forgiveness than ask for permission. Maybe it's the other way around. Whatever the case, to the extent I need to, I'm NOT going to ask for forgiveness for what I say – someone NEEDS to speak up and out!

 

 

Indexes and ETFs: The IBB (+0.09%), XBI (+0.31%) and IWM (+0.16%) are UP and the XLV is NOT indicating

Companies in my headlights:  BUY – AGTC, BLCM, CLLS, JUNO and KITE

SELL – BSTG

 

Dow futures are UP +0.15% and NASDAQ futures are UP 0.17% but gains are being pared as a slide in oil prices accelerates

 

Dow, S&P 500 and NASDAQ futures rose on Tuesday, as stocks in Asia and Europe gained after the first debate between U.S. presidential candidates, Hillary Clinton and Donald Trump.

European stocks erased gains and turned lower in mid-morning trade as weak sentiment towards the banking sector saw Deutsche Bank shares hit a fresh record low.

Asia markets retraced much of their earlier losses to trade mostly higher, following the conclusion of the first U.S. presidential debate.

 

Data docket: the Case-Shiller home price index and the Conference Board's consumer confidence report for September.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Monday, POSITIVE on Friday, Thursday, Wednesday and last Tuesday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Monday closed NEGATIVE with 33 decliners, 9 advancers and 1 flat;
  • Friday closed POSITIVE with 20 decliners, 22 advancers and 1 flat;
  • Thursday closed POSITIVE with 16 decliners, 23 advancers and 4 flats;
  • Wednesday closed POSITIVE  with 17 decliners, 24 advancers and 2 flats;
  • Last Tuesday closed POSITIVE with 18 decliners, 23 advancers and 2 flats;

 

 

Remembering Monday’s closing post, “Remember, nobody has ever gone broke by taking profits, that's why, I say traders are sure to be “lightening the load” as Q3 ends … as development company losses are expected.”

  • The big debate kept us awake with our eyes glued to the TV - only to see which candidate would “screw-up” versus provides us with a preview of their potential governance…

I am such as cynic, the press verdict on the first U.S. presidential debate is that Hillary Clinton 'won', but Donald Trump didn't lose badly enough to really reduce the uncertainty.

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Monday down -1.22% and is UP +0.09% in Tuesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Monday down -0.54% and is UP +0.31% in Tuesday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down -1.16% Monday and is NOT indicating in Tuesday’s pre-market;
  • The iShares Russell 2000 (IWM) closed down -0.99% on Monday and is UP +0.16% in Tuesday’s pre-market.

 

 

Companies in my headlights:

Applied Genetic Technologies (AGTC) closed DOWN -$0.05 to $8.91 following Friday’s $8.96 (+$0.07) after being FLAT at $8.89 on Thursday after Wednesday’s $8.89 (+$0.07) following Tuesday’s $8.82 and last Monday’s $8.58. Forget all the banter and speculation on who is able or might buy whom; let me make it simple, AGTC’s stock is worth $9.87 in cash per share and has NO debt – Maintaining BUY;

Bellicum Pharma (BLCM) closed DOWN -$1.22 to $19.35. BLCM is experiencing a tailwind from KITE’s positive data, the aftermarket indication is positive +$1.19 – BUY;

Biostage (BSTG) closed UP +$0.05 to $1.10. This equity has had a minimal run after a number of conference presentations with low daily volumes. BSTG has a lot of ground to take as a “raise” is needed post the most recent $1.76 offering after the $1.95 offering of 2015. What is the basis of going forward, an IND being filed in 2017, another Orphan Drug designation? What is the patent position and relationship to the Mayo clinic – these issues need to come out.  There are also “rear-view mirror” issues that are NOT easily discarded and seem to reappear. Appreciation is TOO dependent on day-traders who “scurry” for pennies – SELL;

Cellectis SA (CLLS) closed DOWN -$0.63 to $24.82. Last week was a “bummer”; Friday’s close of $25.46 was preceded by $25.72, $25.26 and last Tuesday’s $24.66 and the previous Monday’s $24.39. Oversold and the aftermarket indication is positive +$0.46 – BUY;

Juno Therapeutics (JUNO) closed DOWN -$0.46 to $29.65 following Friday’s -$30.11 and Thursday’s $30.62 after Wednesday’s $31.32 and last Tuesday’s $29.95. JUNO gathers some tailwind from KITE’s positive data. I kept saying last week, that JUNO was oversold. The aftermarket indication is positive +$1.53 – Maintaining BUY;

Kite Pharma (KITE) closed UP +$0.41 to $54.98 following Friday’s $54.57 and Thursday’s to $54.93 (-$0.65) after Wednesday’s $55.58 (-$0.10) following last Tuesday’s $55.68 (-$0.33). KITE reported positive clinical data from a treatment with patients with aggressive non-Hodgkin lymphoma, with shares sharply higher. Last week, I was a bit ostracized for saying accumulate – but, satisfaction is for those who red.  The aftermarket indication is positive +$0.41 – Maintaining BUY;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.